BR112021008725A2 - método para tratar ou prevenir diabetes mellitus tipo 2, método para tratar ou prevenir disfunção endotelial em um indivíduo diabético que sofre de diabetes mellitus tipo 2, e método para tratar ou prevenir sintomas de síndrome metabólica - Google Patents

método para tratar ou prevenir diabetes mellitus tipo 2, método para tratar ou prevenir disfunção endotelial em um indivíduo diabético que sofre de diabetes mellitus tipo 2, e método para tratar ou prevenir sintomas de síndrome metabólica Download PDF

Info

Publication number
BR112021008725A2
BR112021008725A2 BR112021008725-7A BR112021008725A BR112021008725A2 BR 112021008725 A2 BR112021008725 A2 BR 112021008725A2 BR 112021008725 A BR112021008725 A BR 112021008725A BR 112021008725 A2 BR112021008725 A2 BR 112021008725A2
Authority
BR
Brazil
Prior art keywords
aqueous extract
azadirachta indica
weeks
diabetes
group
Prior art date
Application number
BR112021008725-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Muruganandam A. Veeraragavan
Chandan K. Sen
Sanyasi R. Kalidindi
Original Assignee
Natreon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natreon, Inc. filed Critical Natreon, Inc.
Publication of BR112021008725A2 publication Critical patent/BR112021008725A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021008725-7A 2018-11-05 2019-11-05 método para tratar ou prevenir diabetes mellitus tipo 2, método para tratar ou prevenir disfunção endotelial em um indivíduo diabético que sofre de diabetes mellitus tipo 2, e método para tratar ou prevenir sintomas de síndrome metabólica BR112021008725A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201841041788 2018-11-05
IN201841041788 2018-11-05
US16/672,743 US20200138892A1 (en) 2018-11-05 2019-11-04 Anti-diabetic activity of neem extract and synergistic combinations of urolithins a and b
US16/672,743 2019-11-04
PCT/US2019/059774 WO2020097014A1 (en) 2018-11-05 2019-11-05 Anti-diabetic activity of neem extract and synergistic combinations of urolithins a and b

Publications (1)

Publication Number Publication Date
BR112021008725A2 true BR112021008725A2 (pt) 2021-08-03

Family

ID=70460249

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021008725-7A BR112021008725A2 (pt) 2018-11-05 2019-11-05 método para tratar ou prevenir diabetes mellitus tipo 2, método para tratar ou prevenir disfunção endotelial em um indivíduo diabético que sofre de diabetes mellitus tipo 2, e método para tratar ou prevenir sintomas de síndrome metabólica

Country Status (10)

Country Link
US (1) US20200138892A1 (https=)
EP (1) EP3876968A4 (https=)
JP (1) JP2022536223A (https=)
KR (1) KR20210096121A (https=)
CN (1) CN113226347A (https=)
AU (1) AU2019377432A1 (https=)
BR (1) BR112021008725A2 (https=)
CA (1) CA3118926A1 (https=)
MX (1) MX2021005246A (https=)
WO (1) WO2020097014A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022067196A1 (en) * 2020-09-28 2022-03-31 Natreon, Inc. Methods and compositions for improving the immune system and providing immuno-protection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
JP2005325025A (ja) * 2004-05-12 2005-11-24 Green Kanpo Seiyaku Kk 糖尿病予防・治療組成物
EP1807098A1 (en) * 2004-09-13 2007-07-18 Amcod Limited Herbal compositions for treatment of diabetes

Also Published As

Publication number Publication date
JP2022536223A (ja) 2022-08-15
US20200138892A1 (en) 2020-05-07
CA3118926A1 (en) 2020-05-14
WO2020097014A1 (en) 2020-05-14
AU2019377432A1 (en) 2021-06-10
CN113226347A (zh) 2021-08-06
EP3876968A4 (en) 2022-09-14
EP3876968A1 (en) 2021-09-15
MX2021005246A (es) 2021-09-08
KR20210096121A (ko) 2021-08-04

Similar Documents

Publication Publication Date Title
Taheri et al. Urtica dioica‐derived phytochemicals for pharmacological and therapeutic applications
Ansori et al. Medicinal properties of Muntingia calabura L.: A Review
Ahmad et al. Moringa oleifera and glycemic control: A review of current evidence and possible mechanisms
Ruan et al. Borapetoside C from Tinospora crispa improves insulin sensitivity in diabetic mice
Nainu et al. Natural products targeting inflammation-related metabolic disorders: A comprehensive review
Amini et al. Efficacy of Salvia officinalis extract on the prevention of insulin resistance in euglycemic patients with polycystic ovary syndrome: A double-blinded placebo-controlled clinical trial
JP2020172523A (ja) ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び／又は刺激におけるその使用
US9682048B1 (en) Multi-component formulations for the treatment of cognitive decline including Alzheimer's disease
Majeed et al. Novel Emblica officinalis extract containing β-glucogallin vs. metformin: a randomized, open-label, comparative efficacy study in newly diagnosed type 2 diabetes mellitus patients with dyslipidemia
JP2020147590A (ja) 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物
Sarbini et al. The effect of rosella (Hibiscus sabdariffa linn) on insulin resistance in patients with type 2 diabetes mellitus: a randomized clinical trial
Shadnoush et al. Effects of supplementation with curcuminoids on serum adipokines in critically ill patients: A randomized double‐blind placebo‐controlled trial
Bagheri et al. The effects of quercetin on apoptosis and antioxidant activity in a renal ischemia/reperfusion injury animal model
US20130261068A1 (en) Compositions and method for improving endothelial function and cardiovascular health
Sadino et al. An evidence-based review of Morinda citrifolia L.(Rubiaceae) fruits on animal models, human studies, and case reports
Abdulazeez et al. The bio-physiological impact of different concentrations of ginger aqueous extract in Awassi Ewes
US20090285917A1 (en) Composition comprising complex crude drug extracts showing anti-allergic rhinitis, anti-atopic dermatitis and anti-asthma activity
Raja et al. Randomized trial on weight and lipid profile of obese by formulation from Garcina cambogia
US10183047B2 (en) Chromium-containing compositions in combination with Phyllanthus emblica and shilajit having synergistic effects for improving endothelial function and cardiovascular health
BR112021008725A2 (pt) método para tratar ou prevenir diabetes mellitus tipo 2, método para tratar ou prevenir disfunção endotelial em um indivíduo diabético que sofre de diabetes mellitus tipo 2, e método para tratar ou prevenir sintomas de síndrome metabólica
Khaled Effect of ascorbic acid, Balanites aegyptiaca, and strawberry supplementation on glycemic control and renal function biomarkers
US20160015740A1 (en) Chromium-containing compositions for improving endothelial function and cardiovascular health
Gupta et al. Nutraceuticals for diabetes and glucose balance
Agnes Exploring the nutritional benefits of medicinal plants in diabetes management
CN114767696A (zh) 一种低极性人参皂苷药物组合物及其应用

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements